BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints New Executive Leadership Team

CNS Pharmaceuticals (NASDAQ: CNSP) announced that recently appointed President and CEO Rami Levin, in alignment with the board, has recruited Steven O’Loughlin as chief financial officer, Eric Faulkner as chief technology officer and Dylan Wenke as chief business officer, effective March 2, 2026. The company said the appointments support its strategic evolution following a comprehensive review of its pipeline and capital allocation priorities, positioning CNS Pharmaceuticals to advance development programs with a focus on disciplined growth, operational execution and long-term value creation in treatments for brain and central nervous system cancers.

To view the full press release, visit https://ibn.fm/lcSDZ

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.

The Company’s drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears to have both an excellent safety profile and high tolerability among patients.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW
Breaks Categories: News

Recent Posts

BioMedNewsBreaks – Adaptogenics Health Corp. (CSE: ADPT) Advances Peptide Innovation and GLP-1 Companion Strategy

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT)…

21 hours ago

BioMedNewsBreaks – Nanox Imaging Ltd. (NASDAQ: NNOX) Schedules Third Quarter 2026 Financial Results and Conference Call for Nov. 25

Nanox (NASDAQ: NNOX) announced plans to showcase its medical imaging technologies at the Radiological Society…

23 hours ago

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 Operational Highlights and Advances AI-Driven Oncology Pipeline

Lantern Pharma (NASDAQ: LTRN) reported operational highlights and financial results for the third quarter ended…

1 day ago

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Receives USPTO Notice of Allowance for Abuse-Deterrent Fentanyl Patch Brand Names

Nutriband (NASDAQ: NTRB) announced that it received a Notice of Allowance dated Nov. 3, 2026,…

2 days ago

BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Fiscal Q2 2027 Financial Results, Highlights Phase 3 Pipeline Progress

This article has been disseminated on behalf of Helus Pharma and may include paid advertising.…

3 days ago